Detalhe da pesquisa
1.
Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses.
Cell
; 185(23): 4333-4346.e14, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36257313
2.
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Clin Infect Dis
; 76(4): 573-581, 2023 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200701
3.
Undiagnosed COVID-19 in households with a child with mitochondrial disease.
medRxiv
; 2022 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35350208
4.
Comprehensive profiling of the human viral exposome in households containing an at-risk child with mitochondrial disease during the 2020-2021 COVID-19 pandemic.
Clin Transl Med
; 12(11): e1100, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36336785
5.
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir.
medRxiv
; 2022 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734093
6.
Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination.
medRxiv
; 2022 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36093348